Devices Treat Obesity Patients without Options

Early intervention is the general rule for success in treating many diseases, but in obesity, patients have to be in bad shape before they're eligible for the most efficacious treatments, which are surgical interventions. Companies with minimally invasive--and anatomy sparing--devices hope to change that paradigm.

Whether one eats to live or lives to eat, modern man’s relationship with food has clearly gotten out of control. In the US, more than two-thirds of adults age 20 and older are now classified as overweight or obese, to the tune of 127 million overweight adults, 66 million obese adults ,and 9 million morbidly obese adults, according to a report published in February by the Medtech Insight division of Windhover Information. (See, "US Marketsfor Obesity Drugs and Bariatric Surgical Devices".) The US is by no means the only country in which the combination of an increasingly sedentary lifestyle and a diet high in fats has created an obesity epidemic. The prevalence of obesity is increasing across the globe, from Europe to Southeast Asia. Today, more than 1.1 billion adults worldwide are overweight and 312 million of them are obese. What bodes even worse for the future: 155 million children worldwide are overweight or obese according to the World Health Organization.

Health institutions have taken to calling obesity an epidemic, to make it clear that treating it is not an aesthetic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains